Stifel Initiates Coverage On City Therapeutics with Buy Rating, Announces Price Target of $34

Benzinga · 2d ago
Stifel analyst Paul Matteis initiates coverage on City Therapeutics (NASDAQ:CTY) with a Buy rating and announces Price Target of $34.